Novartis's Cancer Treatment Pluvicto Shows Positive Results in Trial

Novartis said Pluvicto demonstrated positive results in patients with PSMA-positive metastatic hormone-sensitive prostate cancer.
The Swiss pharmaceutical company on Monday said Pluvicto showed statistically significant and clinically meaningful benefits—including combined with hormone therapy versus hormone therapy alone—with positive trend in overall survival.

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Associated Press

22 minutes ago

• Associated Press

Benchmark Data for Dealmakers - Access Deal Records of Actual Deals As Disclosed by the Deal Parties

DUBLIN--(BUSINESS WIRE)--Jun 23, 2025-- The 'Precision Medicine Collaboration and Licensing Deals 2019-2025" has been added to offering. This report contains a comprehensive listing of 1,221 precision medicine deals announced since 2019, including financial terms where available, and links to online deal records of actual precision medicine partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Precision Medicine Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the precision medicine deals entered into by the world's leading biopharma companies. Fully revised and updated, the report provides details of precision medicine deals from 2019 to 2025. The report provides a detailed understanding and analysis of how and why companies enter precision medicine deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. The report includes collaboration, development, research, and licensing deals. The initial chapters of the report offer an overview of precision medicine dealmaking. Chapter 1 serves as an introduction, while Chapter 2 outlines the trends in precision medicine dealmaking since 2019. Chapter 3 highlights leading precision medicine deals by headline value, and Chapter 4 lists the top 25 most active companies with summaries and listings of deals. Chapters 5 and 6 provide detailed reviews of deals announced since Jan 2019, organized by contractor availability and technology focus respectively. Precision Medicine Collaboration and Licensing Deals provides the reader with the following key benefits: Precision Medicine Collaboration and Licensing Deals includes: Analyzing contract agreements allows due diligence of: Key Topics Covered: Executive Summary Chapter 1 - Introduction Chapter 2 - Trends in precision medicine dealmaking 2.1. Introduction 2.2. Precision medicine deals over the years 2.3. Most active precision medicine dealmakers 2.4. Precision medicine deals by deal type 2.5. Precision medicine deals by therapy area 2.6. Precision medicine deals by industry sector 2.7. Deal terms for precision medicine deals 2.7.1 Precision medicine deals headline values 2.7.2 Precision medicine deal upfront payments 2.7.3 Precision medicine deal milestone payments 2.7.4 Precision medicine royalty rates Chapter 3 - Leading precision medicine deals 3.1. Introduction 3.2. Top precision medicine deals by value Chapter 4 - Most active precision medicine dealmakers 4.1. Introduction 4.2. Most active precision medicine dealmakers 4.3. Most active precision medicine deals company profiles Chapter 5 - Precision medicine contracts dealmaking directory 5.1. Introduction 5.2. Precision medicine contracts dealmaking directory Chapter 6 - Precision medicine dealmaking by technology type Deal directory Companies Featured For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. View source version on CONTACT: Laura Wood, Senior Press Manager [email protected] For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 KEYWORD: INDUSTRY KEYWORD: BIOTECHNOLOGY GENERAL HEALTH PHARMACEUTICAL HEALTH SOURCE: Research and Markets Copyright Business Wire 2025. PUB: 06/23/2025 01:09 PM/DISC: 06/23/2025 01:08 PM

Bloomberg

22 minutes ago

• Bloomberg

Malaysian Fryer Oil Arbitrage

You can make jet fuel from palm oil. It doesn't even need to be fresh. You can take palm oil, put it in a deep fryer, use it to make french fries, reuse it again and again until it becomes gross and the fries taste bad, and then take the used oil and sell it to a refiner to make jet fuel. Also works with olive oil, soybean oil, lots of cooking oils. This is a very nice fact about the world! You can get jet fuel without (1) drilling for oil or (2) cutting down forests to create dedicated agricultural land just for the jet fuel. You use the existing agricultural land to make cooking oil, you cook with it until it's no longer good, and then when you are done with it you get an extra bonus use as jet fuel. In 2025, this extra bonus use is especially valuable, because energy companies and airlines, at least in Europe, want to demonstrate that they are environmentally sustainable. So finding an environmentally sustainable way to make jet fuel is worth a lot of money to them. Therefore they will pay a lot of money for used cooking oil (or 'UCO').

Yahoo

39 minutes ago

• Yahoo

Jets owner Woody Johnson buys stake in Premier League's Crystal Palace

Woody Johnson is going international. The New York Jets owner has become a familiar face across the pond in recent years, having previously served as the United States ambassador to the United Kingdom during President Donald Trump's first administration. As the NFL's international marketing rights have expanded, teams began vying for exclusive shares of specific markets. Advertisement Johnson's Jets were awarded marketing rights to the UK, making it the green-and-whites' second home under the NFL Global Markets program. Eight other teams have those rights. Now Johnson is digging into the world's game, buying a stake in the Premier League's Crystal Palace. The move was announced by the soccer team on Monday, with ESPN reporting the 43% stake owned by John Textor was sold to Johnson for $254 million. 'Whilst the completion is pending approval from the Premier League and Women's Super League, we do not envisage any issues and look forward to welcoming Woody as a partner and director of the club,' the club said in a statement. Advertisement The sale will have to pass the league's Owners and Directors' Test, something that isn't expected to be a problem. Johnson bought the Jets for $635 million in 2000, an NFL record at the time. He now adds a second professional sports franchise to his portfolio, a trend that is becoming increasingly commonplace across pro sports. Johnson is set to join a Crystal Palace ownership group that includes Washington Commanders owners, Josh Harris and David Blitzer – who each own 18% of the club. The Jets owner previously attempted to buy Chelsea F.C. in 2022, noting he became a fan of the team during his time as ambassador. Now it appears Johnson will be trading in his Chelsea blue for Palace's red-and-blue. This article originally appeared on USA TODAY: Crystal Palace ownership: New York Jets' Woody Johnson buys stake